$INTS
INTENSITY THERAPEUTICS, INC.

2023 Q4 Form 10-Q Financial Statement

#000121390023085791 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.551M $1.139M $622.2K
YoY Change 150.28% 83.01%
% of Gross Profit
Research & Development $1.801M $1.352M $1.161M
YoY Change 102.14% 16.46%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.353M $2.491M $1.783M
YoY Change 121.89% 39.68%
Operating Profit -$2.491M -$1.768M
YoY Change 40.88%
Interest Expense $176.4K $990.00
YoY Change 27467.19%
% of Operating Profit
Other Income/Expense, Net $5.400K $13.23K $7.120K
YoY Change 85.81%
Pretax Income -$3.171M -$2.330M -$1.775M
YoY Change 109.97% 31.26%
Income Tax
% Of Pretax Income
Net Earnings -$3.172M -$2.330M -$1.775M
YoY Change 110.0% 31.26%
Net Earnings / Revenue
Basic Earnings Per Share -$0.17 -$0.52
Diluted Earnings Per Share -$0.23 -$0.17 -$0.14
COMMON SHARES
Basic Shares Outstanding 13.71M shares 13.68M shares 3.410M shares
Diluted Shares Outstanding 13.66M shares 3.410M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.78M $15.69M $696.6K
YoY Change 1026.32% 2153.01%
Cash & Equivalents $8.556M $6.694M $696.6K
Short-Term Investments $6.220M $9.000M
Other Short-Term Assets $6.000K $14.37K $99.82K
YoY Change -92.12% -85.61%
Inventory
Prepaid Expenses $682.0K $971.2K
Receivables
Other Receivables
Total Short-Term Assets $15.46M $16.63M $852.8K
YoY Change 966.23% 1850.56%
LONG-TERM ASSETS
Property, Plant & Equipment $147.0K $152.6K $184.5K
YoY Change 5.69% -17.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.684M $28.44K $167.7K
YoY Change 903.93% -83.05%
Total Long-Term Assets $1.831M $181.0K $352.3K
YoY Change 496.77% -48.61%
TOTAL ASSETS
Total Short-Term Assets $15.46M $16.63M $852.8K
Total Long-Term Assets $1.831M $181.0K $352.3K
Total Assets $17.30M $16.82M $1.205M
YoY Change 884.26% 1295.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.048M $358.4K $796.3K
YoY Change 405.32% -54.99%
Accrued Expenses $891.0K $355.0K $2.525M
YoY Change -52.27% -85.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $2.062M
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.959M $724.0K $5.383M
YoY Change -41.94% -86.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $36.00K $180.9K $36.00K
YoY Change 0.0% 402.47%
Total Long-Term Liabilities $36.00K $180.9K $36.00K
YoY Change 0.0% 402.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.959M $724.0K $5.383M
Total Long-Term Liabilities $36.00K $180.9K $36.00K
Total Liabilities $4.133M $904.9K $5.419M
YoY Change -39.7% -83.3%
SHAREHOLDERS EQUITY
Retained Earnings -$50.50M -$47.34M
YoY Change 30.65%
Common Stock $1.000K $1.371K
YoY Change 193.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.16M $15.91M -$4.214M
YoY Change
Total Liabilities & Shareholders Equity $17.30M $16.82M $1.205M
YoY Change 884.26% 1295.41%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$3.172M -$2.330M -$1.775M
YoY Change 110.0% 31.26%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$947.2K -$5.119M -$3.843M
YoY Change -42.06% 33.2%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $2.821M -$8.844M $0.00
YoY Change
Cash From Investing Activities $2.821M -$8.844M $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -12.16K 20.52M 0.000
YoY Change -100.54%
NET CHANGE
Cash From Operating Activities -947.2K -5.119M -3.843M
Cash From Investing Activities 2.821M -8.844M 0.000
Cash From Financing Activities -12.16K 20.52M 0.000
Net Change In Cash 1.862M 6.558M -3.843M
YoY Change 202.62% -270.66%
FREE CASH FLOW
Cash From Operating Activities -$947.2K -$5.119M -$3.843M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41109
dei Entity Registrant Name
EntityRegistrantName
Intensity Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-1488089
dei Entity Address Address Line1
EntityAddressAddressLine1
1 Enterprise Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 430
dei Entity Address City Or Town
EntityAddressCityOrTown
Shelton
dei Entity Address State Or Province
EntityAddressStateOrProvince
CT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06484-4779
dei City Area Code
CityAreaCode
(203)
dei Local Phone Number
LocalPhoneNumber
221-7381
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
INTS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13709377 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6693825 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1311877 usd
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
8955316 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
971239 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
62924 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
14366 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
75535 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
16634746 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1450336 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
152605 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
139089 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
28438 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
167738 usd
CY2023Q3 us-gaap Assets
Assets
16815789 usd
CY2022Q4 us-gaap Assets
Assets
1757163 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
358404 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
603176 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
355006 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1723400 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
10556 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
143221 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
4348548 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
723966 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6818345 usd
CY2023Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
144891 usd
CY2023Q3 us-gaap Liabilities
Liabilities
904857 usd
CY2022Q4 us-gaap Liabilities
Liabilities
6854345 usd
CY2022Q4 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
10000000 usd
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
15000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
15000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
135000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13709377 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13709377 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3410103 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3410103 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1371 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
341 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
63252862 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
23555160 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47343301 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38653008 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
15910932 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-15097182 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16815789 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1757163 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1351766 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1160737 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2984752 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4241203 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1138748 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
607113 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1981594 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1834966 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2490514 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
1767850 usd
us-gaap Operating Expenses
OperatingExpenses
4966346 usd
us-gaap Operating Expenses
OperatingExpenses
6076169 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2490514 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1767850 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4966346 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6076169 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
147539 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
988 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
148026 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1844 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
15123 usd
us-gaap Interest Expense
InterestExpense
305161 usd
us-gaap Interest Expense
InterestExpense
44877 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2261581 usd
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
13230 usd
CY2022Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
7118 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
18304 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
47646 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2329745 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1774867 usd
us-gaap Net Income Loss
NetIncomeLoss
-7366758 usd
us-gaap Net Income Loss
NetIncomeLoss
-6071556 usd
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
1323535 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2329745 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1774867 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8690293 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6071556 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.78
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13660627 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3410103 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6899984 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3410103 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-15097182 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
975422 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
159262 usd
ints Warrants Issued To Underwriters In Connection With Public Offering
WarrantsIssuedToUnderwritersInConnectionWithPublicOffering
1169719 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3031484 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16468516 usd
ints Overallotment Of Net Issuance Costs
OverallotmentOfNetIssuanceCosts
371583 usd
ints Issuance Of Common Stock In Overallotment For Cash
IssuanceOfCommonStockInOverallotmentForCash
2553417 usd
us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
9999956 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
6998580 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
50000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7366758 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
15910932 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
15133518 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
351169 usd
CY2023Q3 ints Warrants Issued To Underwriters In Connection With Public Offering
WarrantsIssuedToUnderwritersInConnectionWithPublicOffering
152573 usd
CY2023Q3 ints Overallotment Of Net Issuance Costs
OverallotmentOfNetIssuanceCosts
371583 usd
CY2023Q3 ints Issuance Of Common Stock In Overallotment For Cash
IssuanceOfCommonStockInOverallotmentForCash
2553417 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
50000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2329745 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
15910932 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-8684104 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
541333 usd
us-gaap Net Income Loss
NetIncomeLoss
-6071556 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-14214327 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-12480171 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
40711 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1774867 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-14214327 usd
us-gaap Net Income Loss
NetIncomeLoss
-7366758 usd
us-gaap Net Income Loss
NetIncomeLoss
-6071556 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
159262 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
141108 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
133605 usd
us-gaap Share Based Compensation
ShareBasedCompensation
975422 usd
us-gaap Share Based Compensation
ShareBasedCompensation
541333 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2261581 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
110937 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
908315 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-32384 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-61169 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-2353 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-139300 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-244772 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
623797 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1368394 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
986189 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
145899 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
44877 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-142398 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-135645 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6257833 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3842663 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
8844379 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8844379 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
242552 usd
ints Payout Of Fractional Shares On Reverse Split
PayoutOfFractionalSharesOnReverseSplit
44 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
19500000 usd
ints Proceeds From Overallotment Shares
ProceedsFromOverallotmentShares
2925000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
2233348 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
50000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20484160 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5381948 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3842663 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1311877 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4539229 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6693825 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
696566 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
154624 usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
4736999 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
159262 usd
ints Warrants Issued To Underwriter In Connection With Stock Issuance
WarrantsIssuedToUnderwriterInConnectionWithStockIssuance
1169719 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
1323535 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note A — Nature of Business</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Intensity Therapeutics, Inc. (“the Company”) is Connecticut-based and incorporated in Delaware in December 2012. The Company is a biotechnology company whose treatment approach addresses both the regional and systemic nature of a patient’s cancer. The Company’s DfuseRx<sup>SM</sup> technology platform has identified a lead drug, INT230-6.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a result of its initial public offering (“IPO”) that priced on June 29, 2023, the Company began trading on the Nasdaq Capital Market under the symbol “INTS” on June 30, 2023. The IPO closed on July 5, 2023, at which time the Company issued 3,900,000 shares of our common stock and received gross proceeds of $19,500,000 less some of the issuance costs for a cash transfer of $17,765,000. There were additional issuance costs on the IPO of approximately $264,000. The IPO shares were issued on July 5, 2023, the closing date, at the time that the net proceeds were transferred to the Company. On July 7, 2023, the Company sold the full overallotment shares of the IPO. The overallotment resulted in the issuance of 585,000 shares of our common stock, and the Company received $2,691,000 in net cash proceeds. The Company has begun to use and will continue to use the net proceeds from the IPO and overallotment to complete pre-clinical and clinical studies, conduct manufacturing suitable for phase 3 studies, submit regulatory filings to the United States Food &amp; Drug Administration (“FDA”) and for general and corporate purposes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 27, 2023, the Company effected a two-for-one reverse stock split (the “Reverse Stock Split”). All owners of record as of April 27, 2023 received one issued and outstanding share of the Company’s common stock in exchange for two outstanding shares of the Company’s common stock. All fractional shares created by the two-for-one exchange were paid in cash. The conversion price of Series A redeemable convertible preferred stock, Series B convertible preferred stock, and Series C convertible preferred stock were adjusted to reflect the Reverse Stock Split by doubling the original conversion price. The Reverse Stock Split has no impact on the par value per share of the Company’s common stock, Series A redeemable convertible preferred stock, Series B convertible preferred stock, and Series C convertible preferred stock, all of which remain at $.0001. All holders of options and warrants had the exercise price doubled and the number of shares issuable upon exercise reduced by half. All current and prior period amounts related to shares, share prices and loss per share, presented in the Company’s financial statements and the accompanying notes have been restated for the Reverse Stock Split. All preferred stock and convertible notes that were issued during the pre-IPO period were converted into common stock.</p>
CY2023Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
19500000 usd
CY2023Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
264000 usd
CY2023Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On April 27, 2023, the Company effected a two-for-one reverse stock split (the “Reverse Stock Split”). All owners of record as of April 27, 2023 received one issued and outstanding share of the Company’s common stock in exchange for two outstanding shares of the Company’s common stock. All fractional shares created by the two-for-one exchange were paid in cash. The conversion price of Series A redeemable convertible preferred stock, Series B convertible preferred stock, and Series C convertible preferred stock were adjusted to reflect the Reverse Stock Split by doubling the original conversion price. The Reverse Stock Split has no impact on the par value per share of the Company’s common stock, Series A redeemable convertible preferred stock, Series B convertible preferred stock, and Series C convertible preferred stock, all of which remain at $.0001. All holders of options and warrants had the exercise price doubled and the number of shares issuable upon exercise reduced by half. All current and prior period amounts related to shares, share prices and loss per share, presented in the Company’s financial statements and the accompanying notes have been restated for the Reverse Stock Split. All preferred stock and convertible notes that were issued during the pre-IPO period were converted into common stock.
CY2023Q3 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
47300000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
7400000 usd
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
6700000 usd
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
9000000 usd
CY2021Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
8.57
CY2022Q1 ints Number Of Shares Underlying Options Outstanding At Ending
NumberOfSharesUnderlyingOptionsOutstandingAtEnding
911250 shares
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>[2] Use of estimates:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain accounting principles require subjective and complex judgments to be used in the preparation of financial statements. Accordingly, a different financial presentation could result depending on the judgments, estimates, or assumptions that are used.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company utilizes significant estimates and assumptions in valuing its stock-based awards. An additional significant estimate is that these financial statements are based on the assumption of the Company continuing as a going concern. See Note B with regard to the Company’s ability to continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>[3] Concentration of credit risk:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company’s financial instruments that are exposed to concentrations of credit risk consist entirely of cash and investments in U.S. Treasury bills. These financial instruments are held at two U.S. financial institutions. The cash accounts are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. During the nine months ended September 30, 2023 and 2022, the Company’s cash balances exceeded the FDIC insurance limit. The investments in U.S. Treasury bills are not FDIC insured but are backed by the U.S. government. U.S. Treasury bills are subject to market risk if they are sold prior to maturity. The Company has not experienced any losses in such accounts. Although the Company believes that the financial institutions with whom the Company does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so beyond amounts guaranteed by the FDIC.</p>
CY2023Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
0 usd
CY2023Q3 us-gaap Marketable Securities
MarketableSecurities
9000000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1770950 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5299351 shares
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>[14] Reclassifications:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain prior year amounts have been reclassified to conform to current year presentation.</p>
CY2022Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
8.57
CY2023Q3 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
9030000 usd
CY2023Q3 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
8844400 usd
CY2023Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
8955300 usd
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
917807 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
29359 usd
CY2022Q4 us-gaap Prepaid Rent
PrepaidRent
16200 usd
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
53432 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
17365 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
971239 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
62924 usd
CY2023Q3 us-gaap Prepaid Taxes
PrepaidTaxes
8785 usd
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
15903 usd
CY2022Q4 ints Receivable With Related Party
ReceivableWithRelatedParty
46401 usd
CY2023Q3 ints State Income Tax Receivable
StateIncomeTaxReceivable
5581 usd
CY2022Q4 ints State Income Tax Receivable
StateIncomeTaxReceivable
13231 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
14366 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
75535 usd
CY2022Q2 ints Number Of Shares Underlying Options Outstanding At Ending
NumberOfSharesUnderlyingOptionsOutstandingAtEnding
911250 shares
CY2022Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
8.57
CY2022Q4 ints Deposit With Vendor Noncurrent
DepositWithVendorNoncurrent
150000 usd
CY2023Q3 ints Deposit With Landlord Noncurrent
DepositWithLandlordNoncurrent
28438 usd
CY2022Q4 ints Deposit With Landlord Noncurrent
DepositWithLandlordNoncurrent
17738 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
28438 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
167738 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
328527 usd
CY2023Q3 ints Accrued Patient Costs Current
AccruedPatientCostsCurrent
340639 usd
CY2022Q4 ints Accrued Patient Costs Current
AccruedPatientCostsCurrent
1392604 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
14367 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2269 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
355006 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1723400 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2261581 usd
CY2022Q4 ints Convertible Notes Payable Principal Current
ConvertibleNotesPayablePrincipalCurrent
4250000 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
98548 usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
4348548 usd
us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
1399716 shares
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
117700 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2261581 usd
CY2023Q3 us-gaap Share Price
SharePrice
5
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
6
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0146 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0397 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
40950 usd
us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
153000 usd
CY2021Q4 ints Number Of Shares Underlying Options Outstanding At Beginning
NumberOfSharesUnderlyingOptionsOutstandingAtBeginning
911250 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
60000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.5
CY2022Q3 ints Number Of Shares Underlying Options Outstanding At Ending
NumberOfSharesUnderlyingOptionsOutstandingAtEnding
851250 shares
CY2022Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
8.36
CY2022Q4 ints Number Of Shares Underlying Options Outstanding At Beginning
NumberOfSharesUnderlyingOptionsOutstandingAtBeginning
1044250 shares
CY2022Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
8.48
CY2023Q1 ints Number Of Shares Underlying Options Outstanding At Ending
NumberOfSharesUnderlyingOptionsOutstandingAtEnding
1044250 shares
CY2023Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
8.48
CY2023Q2 ints Number Of Shares Underlying Options Outstanding At Ending
NumberOfSharesUnderlyingOptionsOutstandingAtEnding
1044250 shares
CY2023Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
8.48
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
50000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.43
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
12500 shares
CY2023Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2
CY2023Q3 ints Number Of Shares Underlying Options Outstanding At Ending
NumberOfSharesUnderlyingOptionsOutstandingAtEnding
1081750 shares
CY2023Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
8.46
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
801750 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.1
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
85000 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1466000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
280000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
37000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
761000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
430000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2017Q1 us-gaap Area Of Land
AreaOfLand
2534 sqft
CY2017Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P2Y
CY2018Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2020Q3 us-gaap Area Of Land
AreaOfLand
1653 sqm
CY2023Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y6M
CY2023Q3 us-gaap Area Of Land
AreaOfLand
2686 sqm
us-gaap Lease Cost
LeaseCost
46679 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0639 pure
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
54547 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
152605 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
139089 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
10556 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
143221 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
144891 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
155447 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
143221 usd
CY2023Q3 us-gaap Related Party Deposit Liabilities
RelatedPartyDepositLiabilities
36000 usd
CY2022Q4 us-gaap Related Party Deposit Liabilities
RelatedPartyDepositLiabilities
36000 usd
CY2022 ints Related To Agreement
RelatedToAgreement
46400 usd
CY2022 ints Agreement Accrued
AgreementAccrued
95900 usd
ints Expenses Related To Consulting Agreement
ExpensesRelatedToConsultingAgreement
6200 usd
ints Expenses Related To Consulting Agreement
ExpensesRelatedToConsultingAgreement
80900 usd
CY2023Q3 ints Expenses Related To Consulting Agreement
ExpensesRelatedToConsultingAgreement
2200 usd
CY2022Q3 ints Expenses Related To Consulting Agreement
ExpensesRelatedToConsultingAgreement
15000 usd
us-gaap Related Party Tax Expense Due To Affiliates Deferred
RelatedPartyTaxExpenseDueToAffiliatesDeferred
23000 usd
us-gaap Related Party Tax Expense Due To Affiliates Deferred
RelatedPartyTaxExpenseDueToAffiliatesDeferred
50600 usd
CY2022Q3 us-gaap Related Party Tax Expense Due To Affiliates Deferred
RelatedPartyTaxExpenseDueToAffiliatesDeferred
16900 usd
us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
18300 usd
us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
47700 usd
CY2023Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
30300000 usd
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
1 pure
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.03 pure
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
14700 usd
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
29300 usd
CY2023Q3 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
4800 usd
CY2022Q3 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
6000 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
usd
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
usd
CY2023Q3 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q3 us-gaap Interest Expense
InterestExpense
usd
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2023Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
usd
CY2022Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
usd
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.78
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13660627 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3410103 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3410103 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6899984 shares
ints De Deemed Dividend
DeDeemedDividend
usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
ints Payout Of Fractional Shares On Reverse Split
PayoutOfFractionalSharesOnReverseSplit
usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
usd
ints Proceeds From Overallotment Shares
ProceedsFromOverallotmentShares
usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
usd
ints Warrants Issued To Underwriter In Connection With Stock Issuance
WarrantsIssuedToUnderwriterInConnectionWithStockIssuance
usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
usd
CY2023Q3 us-gaap Prepaid Rent
PrepaidRent
usd
CY2023Q3 ints Receivable With Related Party
ReceivableWithRelatedParty
usd
CY2023Q3 ints Deposit With Vendor Noncurrent
DepositWithVendorNoncurrent
usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
usd
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y5M
ints Related To Agreement
RelatedToAgreement
usd
ints Agreement Accrued
AgreementAccrued
usd
CY2023Q3 us-gaap Related Party Tax Expense Due To Affiliates Deferred
RelatedPartyTaxExpenseDueToAffiliatesDeferred
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001567264

Files In Submission

Name View Source Status
ints-20230930_cal.xml Edgar Link unprocessable
0001213900-23-085791-index-headers.html Edgar Link pending
0001213900-23-085791-index.html Edgar Link pending
0001213900-23-085791.txt Edgar Link pending
0001213900-23-085791-xbrl.zip Edgar Link pending
f10q0923ex31-1_intensity.htm Edgar Link pending
f10q0923ex31-2_intensity.htm Edgar Link pending
f10q0923ex32-1_intensity.htm Edgar Link pending
f10q0923ex32-2_intensity.htm Edgar Link pending
f10q0923_intensity.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
f10q0923_intensity_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
ints-20230930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
ints-20230930_lab.xml Edgar Link unprocessable
ints-20230930_def.xml Edgar Link unprocessable
ints-20230930_pre.xml Edgar Link unprocessable
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending